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1. Introduction
Discovery of incretin hormones and their role on glucose metabolism and pathogenesis of type
2 diabetes mellitus (T2 DM) are current interests of diabetology. Incretin hormones are secreted
from intestinal endocrine cells in response to food ingestion and potentiate pancreatic insulin
secretion when compared with iv glucose administration. Since malfunction of incretin
hormones has been found to have role in T2 DM pathogenesis, incretin based therapies have
been developed. Incretin effect, incretine hormones, functions, their role in pathogenesis of T2
DM and management of T2 DM with incretin-based drugs are discussed in this chapter.
2. Incretin effect, incretin hormones, secretion and functions
2.1. The incretin effect
Pancreas secrete insulin in response to the food content in the gastrointestinal lumen. Endo‐
crine pancreas senses food ingestion via incretin hormones, nerve inputs and substrates to
secrete insulin. This chain of secretion which starts with food ingestion and result with insulin
secretion by endocrine pancreas is called enteroinsulinar axis [1, 2]. The first definition of
incretin effect depend on the fact that, much more insulin secretion is induced by oral glucose
than with iv glucose administration. So two-to three fold augmented insulin response to oral
glucose compared with iv glucose is known as the incretin effect [3].
A duodenal exctract has been found to reduce glucosuria first in early 20th century before the
discovery of this phenomenon. The elements of the incretin effect were recognised much more
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before their insulinotropic effects. Glucagon like insulinotropic peptide (GIP) is the first, which
was discovered in 1973 by its inhibitory effect on gastric acid secretion and insulinotropic effect
was defined later. This discovery was followed by the definiton of another intestinal peptide
called glucagon like peptide 1 (GLP-1) ten years later. Discovery of incretin system, and its
pathogenetic role in T2 DM caused an important evolution in pathogenesis and management
of diabetes. This discovery pointed the role of gastrointestinal system and derived peptides
on insulin secretion and glucose metabolism, which has not been taken into account for a very
long time.
Postprandial rate of insulin secretion is assumed to be solely affected by the stimulatory effect
of incretin hormones, and the role of gastrointestinal motility seems not to be accounted.
Passage rate of the ingested foods through the gastrointestinal tract directly affects the
secretion rate, secretion amount and the type of incretin hormone [4-6]. These mentioned
gastrointestinal motility dependent events play an important role on postprandial glucose
homeostasis. Effect of gastrointestinal motor function on glucose metabolism, pathogenesis of
diabetes and glycemic regulation still need to be further evaluated.
2.2. Incretin hormones
There are two incretin hormones known to function on postprandial insulin secretion, which
called GIP and GLP-1. Their malfunction and malsecretion have been shown to have role in
the pathogenesis of T2 DM.
GIP is a large peptide hormone which is processed from a larger prohormone. Expression of
GIP is widely distributed in the body, but the functions are not well understood at these
locations. GIP is secreted from enteroendocrine, so called K cells, which predominantly located
in the proximal duodenal mucosa but may be seen anywhere in the entire intestinal mucosa [7].
The other incretine hormone GLP-1 is derived from proglucagon peptide. Proglucagon gene
is dominantly expressed in pancreatic alpha cells, brain stem and distal intestinal mucosal
endocrine, so called L cells [8]. Posttranslational processing of proglucagon peptide differ
between pancreatic alpha, brain and intestinal cells, resulting with different endproducts
[9-10]. Proglucagon peptide contains two proglucagon peptides named glicentin and major
proglucagon fragment. Pancreas contains these two proglucagon peptides in one molecule and
secrete glucagon along with major proglukagon fragment. Pancreas processes glicentin to
glicentin related pancreatic polypeptide (GRPP), glucagon, and intervening peptide 1 (IP-1),
while major proglucagon fragment is not further processed in pancreas. Intestinal L cells
secrete these two glucagon like peptide seperately. Unlike alpha cells, intestinal cells have the
ability to process major proglucagon fragment to GLP-1, GLP-2 and IP-2. Glicentin is not
cleaved or partly cleaved into GRPP and oxyntomodulin in the intestinal cells [Figure 1].
Mechanism of organ spesific posttranslational progulcagon processing is not fully determined.
Several factors have been defined to have role in organ spesific processing. Transcription factor
named pax6 and the other novel regulator is β-catenin, which is the major effector in Wnt
signalisation system are among these regulators. T cell factor 4 (TCF-4 or known as TCF7L2)
has been discovered to mediate the Wnt pathway, and shown to induce proglucagon gene
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expression to produce GLP-1 in the intestinal endocrine cells, but not in alpha cells [11, 12].
Later a TCF-4 gene polymorphism has been found to be involved in susceptibity to T2 DM.
This is an important evidence which proved a link between disrupted incretin effect and
development of T2 DM.
Active forms of GLP-1 are GLP-1 (7-36) and GLP-1 (7-37). Lower than %25 of total amount of
active form secretion leaves intestine, then 40-50% of this degraded in the liver. In conclusion
a very low amount of active GLP-1 reaches into the systemic circulation [13, 14]. GLP-1 (7-36)
is cleaved by dipeptidylpeptidase 4 (DPP-4) to GLP-1 (9-36). This enzyme is highly expressed
in the brush border of the enterocytes and also in the endothelial cells of the enteric vasculature
[15]. Inactive GLP-1 (9-36) and active GLP-1 (7-36) are also degraded by neutral endopeptidase
24.11 (NEP 24,11) to form another inactive form named GLP-1 (28-36) [16]. Although GLP-1
(9-36) and GLP-1 (28-36) are known as inactive forms, it has been shown that they may be as
beneficial as their active counterparts on glucose metabolism [17, 18]. Active GLP-1 and its
metabolites are cleared from kidneys [19].
Both incretin hormones has been shown to be important in food induced insulin secretion but
their potency and molar secretion amounts differ. GIP is secreted into the circulation 10-fold
higher amount than GLP-1, but the potency of GLP-1 exceeds GIP [20].
Figure 1. Post-translational processing of proglucagon peptide in pancreas, intestine and brain (GRPP: Glicentin relat‐
ed polypeptide, IP-1: intervening peptide 1).
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2.3. Incretin hormone secretion and regulation of secretion
Both incretin hormones are secreted from gastrointestinal endocrine cells response to food
ingestion. Although it is very low in amount, incretins are also has been shown to secreted
during fasting [21]. Proximal intestinal cells secrete GIP, while GLP-1 is secreted from distal
ileal and colonic L cells. It is the amount of ingested foods and the gastric emptying rate which
effect the type of incretin hormone secreted [22, 23]. For example small amounts of food and
a rapid gastric emptying induce GIP secretion, while slow gastric emptying and large complex
food portions induce GLP-1 secretion. The exact mechanism of how food components induce
the selective secretion of incretin hormones are still not clear. Elements of glucose transport
system, such as sodium glucose transporter 1 (SGLT-1) and G protein coupled long chain fatty
acid receptors on L cells has been shown to mediate the pathways which induce enteric
endocrine cells to secrete incretin hormones in a selective manner [24, 25]. In conclusion
incretin hormone levels are very low during fasting state, they are secreted in response to
ingested glucose and lipids. Food ingestion is the trigger which starts enteroinsulinar axis
result with insulin secretion from pancreatic β-cells. Although neuronal pathways modulate
insulin secretion, neuronal pathways do not have role in the induction of enteroinsulinar axis,
since GLP-1 does not increase during cephalic phase of insulin secretion [26].
2.4. Functions of incretin hormones
The incretin GIP shows its actions via a G protein coupled membrane receptor which belongs
to the secretin-glucagon receptor family [27, 28]. The other incretin GLP-1 also shows its effects
on target cells via a G protein coupled GLP-1 receptor (GLP-1R), which is widely expressed in
the body unlike limited secretion sites of GLP-1 [29]. Only one type GLP-1R has been defined
in the body, and the organ spesific effects of GLP-1 is believed to be determined by the
difference in the glycosilation of the receptor. Wide distribution of the receptor such as
endocrine pancreas, brain, heart, gastrointestinal system and kidney, is responsible for the
extrapancreatic and extraintestinal effects of the peptide.
Because GIP has been reported to be nearly not affected in diabetic patients, and there is a clear
evidence of diminished GLP-1 secretion in T2 DM, this chapter will mention GLP-1 as a
representative of incretine hormones [30, 31].
1. Effects of GLP-1 on β-cells:
It has been shown that GLP-1 has insulinomimetic, insulinotropic and insulinotrophic
effects, which mean insulin-like, insulin secretory and regenerative and proliferative
effects respectively.
Insulin-like effect of GLP-1 has been shown in several studies, in which GLP-1 inhbibited
hepatic glucose output [32, 33]. The mechanisms of inhibition of hepatic glucose output
and involving receptors need to be clarified, since hepatocytes do not express GLP-1R.
Insulin secretion is potentiated by GLP-1 only in the presence of glucose. This effect starts
with the interaction between the GLP-1 and its G protein coupled membrane receptor.
GLP-1 induces insulin secretion only in the presence of glucose in the β-cell [34]. GLP-1
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and glucose both increase intracellular cAMP levels sinergistically, then cAMP induces
protein kinase A (PKA) and cAMP regulated guanine nucleotide exchange factor II
(cAMP-GEF II), also known as Epac2. These two system induce β-cells to secrete insulin
by several mechanisms. Closure of ATP sensitive potassium channel and activation of
calcium channels both cause depolarisation of β-cell, and then insulin secretion occurs.
Both calcium derived from intracellular stores and extracellular space contribute in
increase in intracellular calcium levels. Increase in intracellular calcium further stimulate
insulin secretion via granule exocytosis. The latter calcium dependent insulin secretion
may contribute to >70 % of overall GLP-1 induced insulin secretion. Induction of insulin
secretion is not the only effect of GLP-1 on β-cells. Insulin gene promoter region which is
mediated with PKA and possibly mitogen activated protein (MAP) kinase pathway are
also modulated by GLP-1 [35]. Pancreatic duodenal homeobox-1 (PDX-1), which is a key
regulator of developing pancreas, and essential for β-cell growth and insulin gene
transcription in adulthood, has been shown to be regulated by GLP-1 [36]. Intracellular
glucose concentration depends on the function of glucose transporter system, predomi‐
nantly GLUT-2, and β-cells sense the presence of high glucose levels by the action of the
enzyme glucokinase. These two effectors modulate insulin secretion and GLP-1 upregu‐
lates the transcription of glucose transporter and glucokinase genes [37].
Research  on  carcinogenesis  and  embryogenesis  revealed  an  important  intracellular
signaling pathway named wnt. Insulinotropic, pancreatic and extrapanceratic insulino‐
mimetic effects of GLP-1 and possibly its metabolites, has shown to be mediated by
the activation of wnt pathway. Role of GLP-1 metabolites and GLP-1R in the induc‐
tion of  wnt  pathway are  not  clear  [38].  The pathway starts  with  a  wnt  ligand and
LRP5/6-frizzled receptor complex interaction. The cytosolic effector of pathway is β-
catenin (β-cat) and is tightly regulated by a phophorylation-destruction complex. This
complex is formed by glycogene synthase kinase 3β (GSK-3β), casein kinase 1 (CK-1),
axin/conductin,  adenomatosis poliposis coli  (APC),  and phosphorylated extracellular
signal-regulated kinase (pERK) [Figure 2]. When the receptor complex is stimulated by
a wnt ligand, phosphorylation complex which stimulate the degredation of β-cat by
phosphorylation is disrupted. So β-cat escapes from phosphorylation and remains free.
Free  β-cat  then  enter  to  the  nucleus  and  make  complex  with  nuclear  coactivator
transcription factor  named TCF-7.  This  β-cat-TCF-7  complex induce the  target  gene
expression. Effector β-cat is degraded due to phosphorylation when the receptor is not
stimulated.  TCF-7 remain free when β-cat  does not  reach into the nucleus and free
TCF-7 regulates the repression of target genes. The most attractive function of GLP-1
is its insulinotrophic effect, which means a regenerative effect on β-cells and progeni‐
tor cells  of pancreas [39].  Regeneration of β-cells is  maintained by stimulation of β-
cell proliferation and differentiation of ductal epithelial progenitor cells into β-cells by
GLP-1 [40-44]. GLP-1 increases free β-cat in β-cells, which then induce wnt pathway
to  show  its  insulinotrophic  effects  and  decreasing  glucotoxicity  on  β-cells.  Anti-
apoptotic effect of GLP-1 on β-cells has been currently defined and may be a promis‐
ing cure for diabetes [45]. Oxidative stress, which play role in β-cell death is another
possible target of GLP-1. Thioredoxin (TRX), the thiol oxidoreductase is an important
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intracellular  anti-oxidant.  The  function of  TRX is  downregulated by a  binding pro‐
tein,  called TRX binding protein-2 (TBP-2).  This binding protein has been shown to
induce β-cell apoptosis, by increasing intracellular oxidative stress. Intracellular levels
of TBP-2 closely correlate with blood glucose level [46, 47]. Several studies have found
that  GLP-1  decreases  TBP-2  levels,  which  in  turn  increases  intracellular  TRX  and
decreases oxidative stress, and further β-cell damage [47, 48].
Figure 2. The wnt pathway and the role of GLP-1 on wnt pathway (APC:adenomatosis polyposis coli, CK-1: casein
kinase 1, pERK: phosphorylated extracellular signal-regulated kinase, GSK-3β: glycogene synthase kinase 3β, β-cat:be‐
ta catenin, TCF-7: T cell like factor 7) (A and B: Inactive wnt pathway, C: Activation of wnt pathway by a wnt ligand,
D: Activation of wnt pathway by GLP-1).
2. Effects of GLP-1 on alpha cells:
Glucagon plays an important role in pathogenesis of T2 DM. Glucagon hypersecretion
has been shown during both fasting and postprandial states in patients with diabetes [49].
GLP-1 decrease glucagon secretion. The exact mechanism of this inhibition is not yet
elucidated, but the most possible mechanism is the induction of pancreatic somatostatin
secretion, which inhibit the glucagon secretion by paracrine manner [50, 51].
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3. Effects of GLP-1 on gastrointestinal system:
Gastrointestinal system has a central role in nutrient metabolism with its absorption and
endocrine functions. GLP-1 inhibits gastrointestinal system motility, gastrin induced
gastric acid and exocrine pancreatic secretions, which lead to a physiological malabsorp‐
tion state [52, 53]. This malabsorbtive state contributes to alleviation of postprandial
glucose excursions in diabetic patients.
4. Effects of GLP-1 on central nervous system and satiety:
Low levels of GLP-1 in the systemic circulation may not reach to the central nervous
system, but it has been shown that GLP-1 mediated vagal stimulation may play role in
decreased gastrointestinal motility. The effect of GLP-1 on vagal afferent sensorial neurons
may be a local effect, which in turn these afferent neurons transmit the inputs to solitary
tract nucleus, then inhibit the gastrointestinal motility [54, 55]. GLP-1 decreases food
intake by inducing satiety. Hypotalamic satiety centers, predominantly arcuate nucleus
has been shown to express GLP-1 receptors. But the exact mechanism of how peripheral
GLP-1 stimulate these central receptors is not yet elucidated.
5. Pleitropic effects of GLP-1
Nontraditional (pleitropic) effects of GLP-1 and its metabolites is an evolving area of
research. Wide expression of GLP-1R mediate the widespread action of the peptide.
Insulin like effects of GLP-1 has been shown in heart and vasculature. Since cardiovascular
diseases are the major contributor of mortality and morbidity in patients with T2 DM,
scientific concerns about cardiovascular effects of GLP-1 and based therapies are growing.
Preclinical and clinical studies revealed several cardioprotective effects of GLP-1. There
are two possible mechanism of action of GLP-1 on cardivascular system, one via GLP-1R,
and the other one is receptor-independent [56]. Preliminary cinical studies show that
GLP-1 decreases post-ischemic left ventricular dysfunction in patients with coronary heart
disease [57, 58].
Invitro studies revealed that GLP-1 improves endothelial dysfunction via decreasing
TNF-α, PAI-1 and cellular adhesion molecules [59]. But these observations need to be
suggested by clinical studies.
A study with an insulin resistant patient population showed that GLP-1 increases renal
sodium and fluid excretion, which is oppose to the mechanism of hypertension in T2 DM
[60]. This finding raise the possible blood pressure lowering and renoprotective effect of
GLP-1 and based thearpies. Improved endothelial function and anti-oxidant effects of
GLP-1 may be another contributory effect in their renoprotective action.
Favorable effects on lipids is another important metabolic action of GLP-1. Preliminary
studies reveal that GLP-1 decreases triglyceride, apo B-48 and cholesterol levels [61].
GLP-1 is proposed to be a new therapeutic option for neurodegenerative diseases with its
neuroprotective effects which has been shown in animal studies [62].
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3. Contribution of incretin system in the pathogenesis of diabetes
Diabetes is the state of compromised insulin secretion which resulted with hyperglycemia.
Incretin effect is reduced or almost absent in T2 DM [63]. Although the secretion of GIP is
nearly normal, its insulinotropic effect has been shown to be lost in T2 DM [27]. Secretion of
GLP-1 is decreased in contrast to GIP, but its favorable effects on endocrine pancreas and
extrapanceratic sites are preserved in T2 DM [20, 64]. In conclusion, detoriation of both the
effect and secretion of incretin hormones are involved in the pathogenesis of T2 DM. It is not
clear wheter the detoriation of incretin effect is a primary defect in the pathogenesis of diabetes
or not. Studies suggest that incretin hormone detoriation is a secondary defect during pro‐
gression of diabetes. Another important fact is the restoration of insulin secretion with GLP-1
replacement is possible and improve hyperglycemia [65, 66].
There are several mechanisms of action of GLP-1 in T2 DM. The first one is the augmentation
of glucose induced insulin secretion, resulting with improvement in hyperglycemia. Near-
normal improvement in β-cell response to glucose, improvement in the first phase insulin
secretion and completely normalisation of second phase insulin secretion by GLP-1 has been
exactly defined [67]. Although the induction of insulin secretion is lost during chronic GLP-1
administration, glucose lowering action with maintained insulin levels tend do persist.
Reduction in glucagon secretion is another mechanism of antiglycemic effect of GLP-1 [68].
Administration of GLP-1 delays gastric emptying significantly, and results with reduced
postprandial glucose levels [69, 70]. The latter mechanism seems to be lost in chronic fashion.
Based upon these mentioned antiglycemic effects of GLP-1, several pharmacological agents
are developed for the treatment of diabetes, which will be talked about elswhere in this chapter.
4. Incretin based therapies and their role in the management of type 2
diabetes
Effects of incretin hormones on glucose metabolism and contribution of incretins in the
pathogenesis of T2 DM, make these hormones ideal therapeutical targets. Decrease in apetite,
reduction of body weight, improvement in insulin secretion and delay in gastric emptying are
among several favorable effects of GLP-1 infusion [71]. Rapid degradation of bioactive GLP-1
by DPP-4 shortens half life, and limits anti-diabetic effects of GLP-1 [73]. Two treatment
strategies has been developed to overcome this problem, first to develop DPP-4 resistant GLP-1
analogs, and the second to inhibit the degrading enzyme DPP-4. These two groups of medi‐
cations will be discussed in detail.
4.1. Dipeptydyl peptidase-4 inhibitors
These oral agents are approved for treatment of diabetes whose hyperglycemia do not improve
with monotherapy with sullphonylurea, tiazolidinedione and metformin or their dual
combinations. They exert their effects by inhibiting the enzyme which cleaves the incretins and
increase GIP and GLP-1 levels. Sitagliptin, saxagliptin, linagliptin and alogliptin are available
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in US, and vildagliptin is used in outside US. They have the advantage of being weight neutral
and do not cause hypoglycemia except for combinations with sulphonylureas. They have been
shown to be effective and safe when combined with sulphonylurea, tiazolidinedione or
metformin in patients with T2 DM [73]. Usual dose of sitagliptin is 100 mg once daily, and
renal dysfunction necessitate dose reduction (50 mg for patients who have glomerular filtration
rate 50 mL/min and 25 mg for patients with <30 mL/min) [74]. Saxagliptin is used 2.5-5 mg
once a day and the dose should be reduced to 2.5 mg for moderate renal insufficiency. It is also
an effective agent in combinations like sitagliptin [75, 76]. Vildagliptin is used 50 mg twice
daily in T2 DM. Dose adjustment is not necessary in mild renal insufficency, 50 mg daily dose
is suggested in case of modarate and severe renal dysfunction. Linagliptin is used 5 mg daily,
and it differs from other DPP-4 inhibitors with its completely hepatic elimination, which makes
it possible to use in renal dysfunction. Efficacy and safety of linagliptin have been proven in
monotherapy and combination studies [78-80]. Alogliptin is used 25 mg daily and dose
adjustment is necessary in renal dysfunction. It has similar efficacy and safety profiles with
other DPP-4 inhibitors [80].
All of the members of DPP-4 inhibitors seem to have similar efficacy, but their enzymatic
affinity may be different [81, 82]. Their side effects include headache, increased risk of
nasopharyngitis, urinary tract infection, and skin reactions [83]. There are reports about hepatic
dysfunction with alogliptin and vildagliptin. Although the incidence of pancreatitis is not
increased, a population based data suggested an increased frequency of hospitalisation for
pancreatitis among sitagliptin users [84]. There is concern about whether DPP-IV inhibitors
cause panceratic cancer development or not, but a causal relationship has not been established
yet.
Cardiovascular safety of DPP-4 inhibitors is the matter of concern, since cardiovascular
diseases are the most common cause of death in T2 DM patient population and there are several
antidiabetic drugs which have been withdrawn from marketing due to their cardivascular
safety problems. In a study which cardiovascular events was an endpoint, saxagliptine and
metformin showed similar cardiovascular safety pattern, but patients in saxagliptin group
hospitalised more frequently for heart failure when compared with metformin group [85]. Two
other studies showed that neither alogliptin, nor sitagliptin have beneficial or adverse
cardiovascular effects in short term use [86, 87]. Although these studies showed increased or
decreased risks for cardiovascular events with DPP-4 inhibitors in short term use, their long
term cardiovascular safety need to be further evaluated in long term clinical trials.
4.2. GLP-1 receptor agonists
There are two approved synthetic GLP-1R agonist molecules in the marketing. First one is
Exenatide and the second one is Liraglutide. They are approved for T2 DM as an add-on drug
for patients whom glycemic regulation is failed with one or two oral anti-diabetic medication
[88]. Lower hypoglycemia risk is an important advantage of these molecules, which make them
an excellent choice of therapy in patients whom hypoglycemia is of concern. Although they
are as effective as other older anti-diabetic agents in comparison trials, data about their long
term safety, effects on mortality and weight reduction is lacking [89]. Their effects on weight
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reduction has been proven by several studies, in which weight reducion was a secondary
endpoint [90].
4.3. Exenatide
It is the synthetic analog of GLP-1, and it naturally occurs in the saliva of Gila monster
(Heloderma spectum) as Exendin-4. It has 53% aminoacid homology with original GLP-1
molecule and has a long half-life beacuse of its resitance to DPP-4 mediated degradation. It is
approved for T2 DM, as single or an add-on agent with other oral anti-diabetics in US. It can
be combined with all of the oral anti-diabetics except for DPP-4 inhibitors.
It binds to GLP-1R and shows insulinotropic effects of GLP-1 on β-cells in the presence of
glucose. It slows gastric emptying, lowers plasma glucose levels and reduces weight by
inducing satiety like GLP-1 [91, 92]. Insulinotrophic effects has been shown in animal models
[93, 94].
Beneficial effects on hyperglycemia, weight reduction, lipids and blood pressure has been
shown with clinical trials, which has less than 30 weeks of duration [71, 95-99]. Exenatide
reduces a1c levels by aproximately 1%, has lower hypoglycemia risk and hypoglycemia risk
is increased with concurrent use of sulphonylurea. Exenatide causes a significant weight loss,
which seems independent from its nausea inducing effect. Of note, patients experience nause
lose more weight compared with patients who do not have [83, 100]. Preceding type of of drug
is another important factor on weight loss during exenatide use. Patients using metformin
show much more weight loss when compared with patients using sulphonylurea and
tiazolidinedions [100-103].
The most common side effect of exenatide is gastrointestinal, predominantly nausea and rarely
vomitting, which wane with ongoing therapy. Starting with 5 mcg and increasing the dose
after one month to 10 mcg help to overcome nausea. Although risk of pancreatitis among
patients who use incretin based drugs has been shown to be similar to the diabetic patients
who do not use incretin based therapy, hospitalisation for acute pancreatitis may be increased
[84, 104-106]. Insulinotrophic effects of GLP-1 raised concerns about the possibilty of pancreatic
cancer and neuroendocrine tumor risk among patients using incretin-based therapies
[107-110]. There is no data which prove or unprove these issues, so it is suggested to monitor
patients for possible adverse effects affecting pancreas [111]. Although acute renal failure
following exenatide use has been reported, it is difficult to prove direct relationship with
exenatide use and renal failure in this patient population, which is prone to develop acute renal
failure because of concurrent use of nephrotoxic drugs and underlying diabetic nephropathy
[112]. Exenatide is conraindicated in severe renal impairment (creatinine clearance below 30
mL/min), and close follow up for serum creatinine is suggested when initiating therapy and
after the dose titration from 5 to 10 mcg in patients with moderate renal impairment (creatinine
clearance 30-50 mL/min. Gastroparesis and history of past acute pancretitis are the other
contraindications for exenatide use.
Although Exendin-4 is a GLP-1R analog, it shares a %53 homology with human GLP-1, which
leads to development of anti-exendin antibody. It has been shown that anti-exenatide antibody
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development occur in about %40-57 of treated group [103, 113]. In one study the frequency of
anti-exenatide antibody was reported to be more than %70 at the end of 24 weeks, and %40 of
these antibody positive patients did not show further a1c reduction [114].. Although these
mentioned studies have some limitations, ineffectiveness of exenatide due to blocking
antibodies in long term use is possible.
The usual administarion schedule is starting with 5 mcg sc twice a day within 1 hours before
breakfast and diner, and titration to 10 mcg twice a day 1 month later. Exenatide once weekly
sc formulation is also available in US and Europe, and efficacy on hyperglycemia has been
shown [115]. There are studies which compare the efficacy of daily and weekly formulations
of exenatide. The improvement in a1c level seem to be better achieved with weekly formulation
when compared with daily formulation, with similar body weight reduction [116, 117].
4.4. Liraglutide
Liraglutide is a GLP-1 analog which is produced by a recombinant DNA technology. Substi‐
tution of lysine at position 34 by arginine, and attachment of palmitic acid side chain to lysine
group at position 26 of original GLP-1 produce liraglutide. The lipid side chain lead to
formation of a non-covalent bond with albumin, which in turn slows degredation of the
molecule, allowing it to be used once a day sc. Liraglutide shares 97% aminoacid homology
with GLP-1.
Clinical indications are similar with exenatide. Once daily administration of 0.6 mg sc for one
week reduce gastrointestinal side effects. The dose should be increased to 1.2 mg once daily
for one week, and to 1.8 mg once daily if blood glucose remains above the goals [118].
Liraglutide monotherapy and comibination with one or two oral agents are efficacous in
reducing blood glucose and a1c, causing significant weight reduction compared with placebo,
glimepride and sitagliptin [119-121].
Nausea, vomiting and diarrhea are the most common adverse events [119]. The relationship
between liraglutide use and pancreatitis is controversial. Animal studies have shown a
relationship between liraglutide use and benign and mallignant parafollicular C-cell tumors
[122]. It may be a species specific effect and GLP-1R expression of human C-cell has been shown
to be very low [122]. Short term human studies did not show any elevation in calcitonin levels
with liraglutide, but this issue need further evaluation, since it takes a long time for a mallig‐
nant transformation. Liraglutide is not recommended for use in patients who have medullary
thyroid carcinoma or a related syndrome, or a family history of these diseases.
4.5. Is one GLP-1 receptor agonist superior to the other?
In a 26 week trial comparing the effects of liraglutide and exenatide showed a beter glycemic
control with liraglutide compared with exenatide, with similar weight loss and adverse effects
[123]. In another study the effects of both analogs on hyperglycemia was similar, with slightly
better weight reduction in liraglutide group [124]. One potential superiority of liraglutide to
exenatide may be its molecular homology to GLP-1, which is not associated with development
of blocking antibodies causing drug ineffectiveness during chronic use.
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Besides their beneficial effects like weight reduction and low frequency of hypoglycemia, long-
term safety data, effect on diabetic macro and microvascular complications and mortality of
these GLP-1R analogs are still lacking.
5. Summary
The role of comperatively older drugs such as insulin, insulin secretagogues, metformin,
thiazolidinediones and alpha glucosidase inhbitors in the management of diabetes are familiar
aspects of diabetes therapy. These medications target insulin secretion, insulin sensitivity and
glucose absorption, which may be intrepreted as having limited targets in the pathogenesis of
diabetes. Definition of incretin hormones and their role on β-cell function and survival are the
new aspects of the pathogenesis of diabetes, and management of hyperglycemia. Besides the
novelty of incretin based therapies in the management of diabetes, their roles on β-cell function
and regeneration, which are really promising effects for an anti-diabetic agent are so interesting
and need to be observed in long term clinical practice. Possible effects of these drugs that is
associated with their pleitropic effects, which have been shown in invitro studies on diabetes
related complications are the new era in diabetology. In our opinion the role of incretin besed
therapies in the progression of diabetes and diabetic complications will be determined in the
future, although fovarable or not.
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